Manageable safety profile at both expansion doses, consistent with known adverse events observed with each agent alone, with no treatment related serious adverse events observed at the IDE397 30mg and ...
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that the first patient has been enrolled in its Phase 1 clinical trial evaluating IDE892, an ...
"This study establishes MTAP-del as a biomarker in bladder cancer. We are now ready for a trial in MTAP-del bladder cancer in combination with other inhibitors of the pathway." --Joaquim Bellmunt, MD, ...
Insilico Medicine is heading to the clinic with its seventh pipeline candidate discovered and designed using generative artificial intelligence (AI), a treatment for methylthioadenosine phosphorylase ...
BMS-986504, a first-in-class methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) targeting agent, showed promising antitumor activity in heavily pretreated patients with ...
“In breast cancer, MTAP downregulation activates ornithine decarboxylase (ODC) which in turn leads to formation of putrescine which promotes tumor migration, invasion and angiogenesis [15].” “We ...
Shares of Tango Therapeutics TNGX surged 36.3% on Thursday to a record high after Erasca ERAS announced a clinical trial ...
US-based digital networking solutions provider mTap has announced its launch in India, offering a platform for individuals and businesses to make lasting connections. mTap's digital business card ...
IDEAYA Biosciences begins patient dosing in phase 1 trial of IDE892, a potential best-in-class PRMT5 inhibitor for MTAP-deleted solid tumours: South San Francisco, California Tues ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results